{"nctId":"NCT02600611","briefTitle":"Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1","startDateStruct":{"date":"2015-11-01","type":"ACTUAL"},"conditions":["Skin Structures and Soft Tissue Infections"],"count":600,"armGroups":[{"label":"iclaprim","type":"EXPERIMENTAL","interventionNames":["Drug: iclaprim"]},{"label":"vancomycin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: vancomycin"]}],"interventions":[{"name":"iclaprim","otherNames":["MTF-100"]},{"name":"vancomycin","otherNames":["Vancocin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. written informed consent;\n2. ≥18 years of age;\n3. a bacterial infection of the skin with a lesion size area of at least 75 cm2;\n4. a major cutaneous abscess, cellulitis/erysipelas, and/or wound infections;\n5. the presence of purulent or seropurulent drainage or at least three signs and symptoms of infection (discharge, erythema, swelling, warmth, or pain).\n\nExclusion Criteria:\n\n1. severely impaired arterial blood supply such that amputation of the infected anatomical site is likely;\n2. infected diabetic foot ulcers;\n3. infected decubitus ulcers;\n4. necrotizing fasciitis or gangrene;\n5. uncomplicated skin or skin structure infection;\n6. infections associated with a prosthetic device;\n7. suspected or confirmed osteomyelitis;\n8. conditions requiring systemic anti-microbial treatment, prophylaxis, or suppression therapy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"≥20% Reduction in Lesion Size at 48 to 72 Hours Compared to Baseline in All Randomized Patients.","description":"≥20% reduction in lesion size at 48 to 72 hours (Early Time Point \\[ETP\\]) compared to baseline in all randomized patients (ITT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9","spread":null},{"groupId":"OG001","value":"81.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Resolution or Near Resolution of Lesion at Test of Cure Visit","description":"Resolution or near resolution of lesion at Test of Cure (TOC) visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"248","spread":null},{"groupId":"OG001","value":"262","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":298},"commonTop":["Adverse effects"]}}}